UBS Bets on Viking’s VK2735 to Stand Out in Crowded Obesity Market with $94 Target
VK2735 shows rapid weight loss in Phase 2, with financing through 2027.
VK2735 shows rapid weight loss in Phase 2, with financing through 2027.
Late-stage alopecia areata biologic trading near cash, funded through data.
Biogen shares rose after JPMorgan upgraded the stock to Overweight with a $300 target, pointing to key clinical readouts expected in 2027.
Targets imply 88% to 314% upside, with cash into 2027-2030.
Rocket’s RP-A501 Danon update led Goldman to Neutral and a $4 target. Clinical risk looks lower, but peak sales stay in doubt.
JPMorgan started Savara at Overweight and $12, pointing to a Nov. 22 FDA decision, later U.K. and EU reviews, and blockbuster potential.